Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer

重新利用他汀类药物以增强 BCL-2 拮抗剂治疗血癌的疗效

基本信息

  • 批准号:
    9178942
  • 负责人:
  • 金额:
    $ 17.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-15 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary The goal of this proposal is to evaluate the feasibility of using HMGCR inhibitors (statins) to enhance efficacy of ABT-199 in preclinical models of B cell cancers. ABT-199 (venetoclax) is a small molecule inhibitor of BCL-2, a key pro-survival protein that is highly expressed in many leukemias and lymphomas. Statins are commonly used to control plasma cholesterol levels and are among the most widely prescribed medications worldwide. However, statins are also known to have anti-cancer potential. We have observed potent synergy of statins combined with ABT-199 in human cell lines derived from diffuse large B cell lymphoma (DLBCL). This synergy is also seen in murine B lymphoma cells derived from a genetically engineered mouse model. Using a BH3 profiling assay, we observed that simvastatin increases mitochondrial priming, correlating with its ability to synergize with ABT-199. Mechanistic studies support the hypothesis that statins prime lymphoma cells for apoptosis by blocking prenylation pathways downstream of mevalonate production by HMG-CoA-reductase. In this proposal we will build on these findings to address the feasibility of the statin/ABT-199 combination. The first Aim is to determine whether statins can achieve pharmacological exposure in tumor cells at a clinically relevant dose. We will compare three different statins in a mouse lymphoma model to identify the optimal statin and minimal dose with pharmacodynamic activity. The second Aim will be to evaluate the efficacy and toleratibility of the statin/ABT-199 combination in lymphoma models. Using a mouse syngeneic B cell lymphoma driven by BCL-2 and MYC, we will assess differences in lymphoma outgrowth and mouse survival, and correlate with a pharmacodynamic marker of statin action. We will also examine drug effects on survival of primary human lymphoma cells in vitro. In parallel we will measure the impact of drug treatments on normal lymphocytes using both the in vivo mouse model, and using peripheral blood mononuclear cells from healthy human volunteers. The third Aim is to test whether mitochondrial priming provides a predictive biomarker of statin efficacy. Using dynamic BH3 profiling, we will determine whether increased mitochondrial priming by statins correlates with response to the statin/ABT-199 combination. Together these experiments will establish efficacy, tumor selectivity, and a predictive biomarker for the combination of statins plus ABT-199, providing proof-of-concept to support future clinical trials in aggressive lymphomas.
项目摘要 本提案的目的是评估使用HMGCR抑制剂(他汀类药物)增强 ABT-199在B细胞癌临床前模型中的功效。ABT-199(venetoclax)是一种小分子 BCL-2的抑制剂,BCL-2是一种关键的促生存蛋白,在许多白血病中高度表达, 淋巴瘤他汀类药物通常用于控制血浆胆固醇水平, 在全球范围内广泛使用的药物。然而,他汀类药物也被认为具有抗癌作用, 潜力我们在人细胞系中观察到他汀类药物与ABT-199联合的有效协同作用 来源于弥漫性大B细胞淋巴瘤(DLBCL)。这种协同作用也见于鼠B淋巴瘤 来自基因工程小鼠模型的细胞。使用BH 3分析测定,我们观察到 辛伐他汀增加线粒体启动,与其与ABT-199协同作用的能力相关。 机制研究支持他汀类药物引发淋巴瘤细胞凋亡的假设, 通过HMG-CoA还原酶阻断甲羟戊酸生产下游的异戊二烯化途径。在这 我们将在这些发现的基础上提出他汀类药物/ABT-199联合治疗的可行性。 第一个目的是确定他汀类药物是否可以在肿瘤细胞中达到药理学暴露, 临床相关剂量。我们将在小鼠淋巴瘤模型中比较三种不同的他汀类药物, 最佳他汀类药物和具有药效活性的最小剂量。第二个目标是 评价他汀类/ABT-199组合在淋巴瘤模型中的功效和耐受性。使用 小鼠同基因B细胞淋巴瘤由BCL-2和MYC驱动,我们将评估差异, 淋巴瘤生长和小鼠存活,并与他汀类药物的药效学标志物相关 行动上我们还将研究药物对体外原代人淋巴瘤细胞存活的影响。在 同时,我们将测量药物治疗对正常淋巴细胞的影响, 小鼠模型,并使用来自健康人类志愿者的外周血单核细胞。的 第三个目的是测试线粒体引发是否提供他汀类药物功效的预测性生物标志物。 使用动态BH 3分析,我们将确定他汀类药物是否增加了线粒体启动, 与对他汀类药物/ABT-199组合的反应相关。这些实验将共同建立 他汀类药物加ABT-199组合的疗效、肿瘤选择性和预测性生物标志物, 提供概念验证,以支持未来在侵袭性淋巴瘤中的临床试验。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID Alexander FRUMAN其他文献

DAVID Alexander FRUMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID Alexander FRUMAN', 18)}}的其他基金

Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer
重新利用他汀类药物以增强 BCL-2 拮抗剂治疗血癌的疗效
  • 批准号:
    9316613
  • 财政年份:
    2016
  • 资助金额:
    $ 17.85万
  • 项目类别:
Regulation of B cell differentiation by eIF4E
eIF4E 对 B 细胞分化的调节
  • 批准号:
    9244731
  • 财政年份:
    2016
  • 资助金额:
    $ 17.85万
  • 项目类别:
Combination strategies to enhance therapy for Ph-like B-ALL
增强 Ph 样 B-ALL 治疗的联合策略
  • 批准号:
    8912208
  • 财政年份:
    2015
  • 资助金额:
    $ 17.85万
  • 项目类别:
UCI-GPS: UC Irvine Graduate Professional Success
UCI-GPS:加州大学欧文分校毕业生职业成功
  • 批准号:
    9341983
  • 财政年份:
    2014
  • 资助金额:
    $ 17.85万
  • 项目类别:
UCI-GPS: UC Irvine Graduate Professional Success
UCI-GPS:加州大学欧文分校毕业生职业成功
  • 批准号:
    8929336
  • 财政年份:
    2014
  • 资助金额:
    $ 17.85万
  • 项目类别:
UCI-GPS: UC Irvine Graduate Professional Success
UCI-GPS:加州大学欧文分校毕业生职业成功
  • 批准号:
    8829529
  • 财政年份:
    2014
  • 资助金额:
    $ 17.85万
  • 项目类别:
Solving the elusive mechanism of rapamycin action in lymphocytes
解决雷帕霉素在淋巴细胞中作用的难以捉摸的机制
  • 批准号:
    8285697
  • 财政年份:
    2012
  • 资助金额:
    $ 17.85万
  • 项目类别:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
用于白血病治疗的 TOR 激酶抑制剂:作用机制和耐药性
  • 批准号:
    8628792
  • 财政年份:
    2012
  • 资助金额:
    $ 17.85万
  • 项目类别:
Solving the elusive mechanism of rapamycin action in lymphocytes
解决雷帕霉素在淋巴细胞中作用的难以捉摸的机制
  • 批准号:
    8531852
  • 财政年份:
    2012
  • 资助金额:
    $ 17.85万
  • 项目类别:
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
用于白血病治疗的 TOR 激酶抑制剂:作用机制和耐药性
  • 批准号:
    8815271
  • 财政年份:
    2012
  • 资助金额:
    $ 17.85万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 17.85万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了